"Arcus and AstraZeneca enter trial collaboration for renal cancer treatment" was originally created and published by Clinical ...

Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced ...

Wednesday announced a clinical trial collaboration agreement with AstraZeneca (AZN) to evaluate casdatifan in combination with volrustomig for the treatment of clear cell renal cell carcinoma or ccRCC ...

US clinical-stage biotech Arcus Biosciences has entered into a clinical trial collaboration with AstraZeneca on renal cancer ...

Arcus Biosciences develops late-stage immunotherapies, with Domvanalimab and Casdatifan leading the way. See why I rate RCUS ...

“We believe casdatifan has best-in-class potential, based on the observed PK and PD profiles and the emerging clinical data from our ARC-20 study in patients with ccRCC,” said ...

The partnership will explore the potential of casdatifan, Arcus's investigational HIF-2a inhibitor, in conjunction with AstraZeneca's investigational PD-1/CTLA-4 bispecific antibody, volrustomig.

The partnership will explore the potential of casdatifan, Arcus's investigational HIF-2a inhibitor, in conjunction with AstraZeneca's investigational PD-1/CTLA-4 bispecific antibody, volrustomig. The ...

Lam Research Corp. today announced that the company will host its quarterly financial conference call and webcast on Wednesday, October 23, 2024, beginning at 2:00 p.m. Pacific Daylight Time (5:00 p.m ...

Universal Health Services, Inc. announced today that it will report results for its third quarter ended September 30, 2024, after the market closes on Thursday, October 24, 2024. There will be a ...